InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage
biopharmaceutical company developing anti-inflammatory therapeutics
by targeting the complement system, announced today the pricing of
its underwritten public offering of 9,411,765 ordinary shares at an
offering price of $4.25 per ordinary share. The offering is
expected to close on April 14, 2023, subject to the satisfaction of
customary closing conditions.
The Company has granted the underwriters a
30-day option to purchase up to 1,411,764 additional ordinary
shares at the public offering price, less the underwriting
discount.
The Company intends to use the net proceeds from
the offering to fund the continued development of vilobelimab,
general research and development expenses and investments in the
Company’s commercial infrastructure and for working
capital and general corporate purposes.
Raymond James & Associates, Inc. is serving
as sole book-running manager for the offering, and LifeSci Capital,
LLC as co-manager.
A shelf registration statement relating to the
securities being sold in this offering was declared effective by
the U.S. Securities and Exchange Commission (the “SEC”) on July 17,
2020. The offering will be made only by means of a prospectus and
prospectus supplement. The prospectus supplement and accompanying
prospectus related to the offering will be filed with the SEC and
will be available at the SEC’s website located at www.sec.gov. When
available, copies of the prospectus supplement and accompanying
prospectus related to the offering may be obtained by contacting
Raymond James & Associates, Inc., Attention: Equity Syndicate,
880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone
at (800) 248-8863, or by email at prospectus@raymondjames.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx GmbH (in Germany) and InflaRx
Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx
N.V. (together “InflaRx”).
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a / C5aR technologies to discover and develop first-in-class
or best-in-class, potent and specific inhibitors of C5a and C5aR.
Complement C5a and its receptor C5aR are powerful inflammatory
mediators involved in the progression of a wide variety of
autoimmune and other inflammatory diseases. InflaRx was founded in
2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA.
Contacts:
InflaRx N.V.Email: IR@inflarx.de
MC Services AGKatja Arnold, Laurie Doyle, Dr.
Regina LutzEmail: inflarx@mc-services.euEurope: +49 89-210 2280US:
+1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, including statements about the closing of the public
offering. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “estimate,” “believe,”
“predict,” “potential” or “continue,” among others. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, the timing, progress and results of clinical
trials of our product candidates and statements regarding the
timing of initiation and completion of studies or trials and
related preparatory work, the period during which the results of
the trials will become available, the costs of such trials and our
research and development programs generally; our interactions with
regulators regarding the results of clinical trials and potential
regulatory approval pathways, including related to our biologics
license application, or BLA, submission for Gohibic (vilobelimab),
and our ability to obtain and maintain full regulatory approval of
vilobelimab or Gohibic (vilobelimab) for any indication; our
ability to leverage our proprietary anti-C5a and anti-C5aR
technologies to discover and develop therapies to treat
complement-mediated autoimmune and inflammatory diseases; our
ability to protect, maintain and enforce our intellectual property
protection for vilobelimab and any other product candidates, and
the scope of such protection; whether the Food and Drug
Administration, or the FDA, European Medicines Agency, or the EMA,
or comparable foreign regulatory authority will accept or agree
with the number, design, size, conduct or implementation of our
clinical trials, including any proposed primary or secondary
endpoints for such trials; the success of our future clinical
trials for vilobelimab and any other product candidates and whether
such clinical results will reflect results seen in previously
conducted preclinical studies and clinical trials; our expectations
regarding the size of the patient populations for, market
opportunity for, coverage and reimbursement for and clinical
utility of Gohibic (vilobelimab) in its approved or authorized
indication or for vilobelimab and any other product candidates, if
approved for commercial use; our manufacturing capabilities and
strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing
methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage
additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for
the finished product Gohibic (vilobelimab); our estimates of our
expenses, ongoing losses, future revenue, capital requirements and
our needs for or ability to obtain additional financing; our
expectations regarding the scope of any approved indication for
vilobelimab; our ability to defend against liability claims
resulting from the testing of our product candidates in the clinic
or, if, approved, any commercial sales; our ability to
commercialize Gohibic (vilobelimab) or our other product
candidates; if any of our product candidates obtain regulatory
approval, our ability to comply with and satisfy ongoing
obligations and continued regulatory overview; our ability to
comply with enacted and future legislation in seeking marketing
approval and commercialization; our future growth and ability to
compete, which depends on our retaining key personnel and
recruiting additional qualified personnel; our competitive position
and the development of and projections relating to our competitors
in the development of C5a and C5aR inhibitors or our industry; and
the risks, uncertainties and other factors described under the
heading “Risk Factors” in InflaRx’s periodic filings with the SEC.
These statements speak only as of the date of this press release
and involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and
other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
InflaRx NV (NASDAQ:IFRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024